4
Changes in Ownership
GeneDx Holdings Corp. Filed Acc 0001689575-26-000019
CHIEF EXECUTIVE OFFICER sold 17,179 shares at an average $76.80 ($1,319,291)
- CHIEF EXECUTIVE OFFICER acquired 30,671 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-03-15 | Option exercise | +11,921 | 56,876 | D | ||
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-03-16 | Option exercise | +18,750 | 75,626 | D | ||
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-03-16 | Sale | −7,178 | $76.35 | $548,035 | 68,448 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-03-16 | Sale | −9,229 | $77.05 | $711,090 | 59,219 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-03-16 | Sale | −772 | $77.94 | $60,166 | 58,447 | D |
| Derivatives | |||||||
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-03-15 | Option exercise · Restricted Stock Unit | −11,921 | 35,763 | D | ||
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-03-16 | Option exercise · Restricted Stock Unit | −18,750 | 75,000 | D | ||
| Open-market sales · 17,179 sh · avg $76.80 · $1,319,291 | |||||||
Loading xslF345X05/form4-03172026_100354.xml…